About Us
M-Tubulin™ is a wholly owned subsidiary of M-Life™ for the purpose of advancing tubulin-based cancer therapeutics through clinical trials
About M-Life™
Learn more about our parent company and the proprietary artificial intelligence based algorithms developed over a decade-long effort.
Dr. Peter Crooks
CDO & Principal M.Sc., Ph.D., D.Sc. (Manc), FRSC, FRPharmS, CSci, CChem
,Founded in 2021, M-Tubulin™ initiated operations as a wholly owned subsidiary of M-Life™ whose purpose is to advance tubulin-based cancer therapeutics through clinical trials. The Company’s cancer drug development program is based on the pioneering cancer research of Dr. Peter Crooks (M-Life Chief Discovery Officer), developer of the on-market cancer drug Valchlor® .
Despite the many general advancements in cancer therapeutics, many malignancies remain lethal and difficult to treat. Embracing the philosophy that new effective treatments must address both the tumor and the entire microenvironment, the Company’s research centered on developing agents that slow tumor growth and the propensity for metastasis. The two targets identified for this effort are tubulin and NF-κB targeted. Utilizing M-Life’s™ Artificial Intelligence platform MiST™ and P2L™, provide a virtual representation of the human body (both efficacy and toxicity), molecules were designed, tested, evaluated and optimized. Out of this effort, dual tubulin/NF-κB based molecules have been vetted for efficacy and toxicity both in silico and via animal and cell culture testing.
The Team is composed of innovators and pioneers in the underlaying fields of M-Life’s™ technology. These fields include chemistry, chem-bioinformatics, biology, translational medicine, advanced mathematics, computer science, engineering, and physics. The Team holds patents and/or published seminal works on pattern recognition, molecule design, molecular synthesis, artificial intelligence, machine learning, advanced data structures, bio-informatics, toxicology, biology, target & phenotypical based discovery, proteomics, genomics as applied the development of new drugs, diagnostics, pathogen detection, molecular discovery, telecommunications, image processing and other technologies.
Dr. Peter Crooks
CDO & Principal M.Sc., Ph.D., D.Sc. (Manc), FRSC, FRPharmS, CSci, CChem
Founded in 2021, M-Tubulin™ initiated operations as a wholly owned subsidiary of M-Life™ whose purpose is to advance tubulin-based cancer therapeutics through clinical trials. The Company’s cancer drug development program is based on the pioneering cancer research of Dr. Peter Crooks (M-Life Chief Discovery Officer), developer of the on-market cancer drug Valchlor® .
Despite the many general advancements in cancer therapeutics, many malignancies remain lethal and difficult to treat. Embracing the philosophy that new efficacious treatments must address the entire tumor microenvironment, the Company’s research centered on slowing tumor growth and decreasing the propensity for metastasis. The two targets identified for this effort are tubulin and NF-κB. Utilizing M-Life’s™ Artificial Intelligence platform MiST™ and P2L™, provide a virtual representation of the human body–both efficacy and toxicity. Out of this effort, dual tubulin/NF-κB based molecules have been vetted for efficacy and toxicity both in silico and via animal and cell culture testing.
The Team is composed of innovators and pioneers in the underlaying fields of M-Life’s™ technology. These fields include chemistry, chem-bioinformatics, biology, translational medicine, advanced mathematics, computer science, engineering, and physics. The Team holds patents and/or published seminal works on pattern recognition, molecule design, molecular synthesis, artificial intelligence, machine learning, advanced data structures, bio-informatics, toxicology, biology, target & phenotypical based discovery, proteomics, genomics as applied the development of new drugs, diagnostics, pathogen detection, molecular discovery, telecommunications, image processing and other technologies.
Virtual Representation of the Human Body
Comprehensive assessment of drugs and new molecules from docking to phenotypical response.
Industry First Virtual Toxicity
Adverse effects from nutropenia to ocular toxicity along with the underlying molecular ‘causality’. Included in our algorithmic portfolio is mitochondrial toxicity–a first in the industry.
Active Moiety Identification & Optimization
Unneeded molecular substituants give rise to potential adverse effects. Our molecules are engineered to contain only the features necessary to produce efficacy.